At a Glance
- Company: Frontage Laboratories, Inc.
- Locations: United States and China
- Headline: Strategic expansion of early-phase clinical research
- Focus area: Phase 1 trials, bioanalysis and clinical services
- Next steps: Enhanced support for global drug development
What happened?
Frontage Laboratories announced expansion of its early-phase clinical research capabilities across the United States and China on 30 January 2026. The CRDMO aims to deliver accelerated, high-quality clinical solutions to pharmaceutical and biotech partners through enhanced infrastructure and integrated services.
Why does it matter?
Early-phase trials often bottleneck global development due to capacity constraints and regulatory complexities; dual-market expansion enables seamless US/EU/Asia bridging studies, faster first-in-human data and reduced timelines for sponsors seeking global reach.
Who’s behind it?
Frontage, a global CRDMO with 25+ years’ experience, provides end-to-end services from discovery to manufacturing across 26 sites. Expansion builds on recent GMP facility openings and positions the firm to capture rising Phase 1 demand.
How was it achieved?
Strategic investments enhance Phase 1 units, bioanalytical labs and central operations in key geographies, integrating with Frontage’s DMPK, formulation and manufacturing strengths for one-stop early development.
What’s next?
Frontage will support clients with expanded capacity for first-in-human, SAD/MAD and proof-of-concept studies, targeting faster regulatory progression and global programme alignment.
What are people saying?
Frontage highlighted the move as strengthening “high-quality clinical development solutions” for partners navigating complex global timelines.